– Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 – Presentation to be featured in the plenary session...
New data include secondary endpoint analyses of clinical responder rates at Day 7, End of Treatment, and Test of Cure, and pre-specified analyses of the clinical responder rates by final diagnosis at Day 14 New MRSA data shows that the increased response previously...
CStone Pharmaceuticals (the “Company” or “CStone”; HKEX: 2616) announces that the first patient has been successfully enrolled and dosed in a Phase III clinical trial assessing CS1001, China’s first fully human, full-length anti-PD-L1...
A woman has given birth to a ‘three-parent baby’ in the first ever clinical trial to test the controversial procedure. The 32-year-old Greek woman had four failed IVF attempts before she heard about the trial by Spanish doctors. The Barcelona-based team used a...
Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1 Cost effective analysis used...
Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean HBsAg change of 0.8log10 with a range of 0.5log10 – 1.4log10...
Email
Text